glp-1 nmda GLP-1-directed receptor antagonism for obesity treatment Incretin Hormones GLP-1 and GIP

In contrast, in 2018, the long-acting GIPGLP-1 co-agonist tirzepatide was found to have substantial glucose-lowering and weight loss properties, to a greater extent than that achieved by GLP-1R agonism with dulaglutide [68], findings replicated in Phase III trials comparing tirzepatide with semaglutide in people with type 2 diabetes [69]

Emerging data suggest that in the context of weight loss induced by GLP-1 medications, incorporating resistance training (rather than relying solely on aerobic or walking activity) helps preserve lean mass

The vote, when it came, was a formality eleven voices in turn, none objecting

Lifestyle factors remain fundamental to treatment success

Many people worry about these side effects

This approval was an important milestone because it moved the conversation beyond weight loss alone